Primary and secondary bacteremia caused by Proteus spp.: epidemiology, strains susceptibility and biofilm formation

• Autorzy: Kwiecinska-Pirog J. , Skowron K. , Gospodarek-Komkowska E.
• Języki publikacji: EN

Abstrakty

EN

Proteus spp. is an etiological factor of urinary tract and bloodstream infections. The aim of this study was the retrospective analysis of susceptibility of Proteus spp. strains isolated from bloodstream infections (BSIs) as well as similarity evaluation of the strains isolated from different clinical samples. Proteus spp. strains were isolated in 2009–2017 from hospital patients. Identification was based on the colony’s morphology and biochemical or MALDI-TOF MS analyzes. The antibiotic susceptibility test was done using the diffusion method. Biofilm formation was evaluated with microplate method using TTC. Bacteremia caused by Proteus spp. was found in 97 patients, mainly secondary to urinary tract infection. Most of the strains were susceptible to piperacillin with tazobactam (95.9%) and amikacin (86.7%). Elderly patients have a higher risk of mortality after BSIs caused by Proteus spp. A detailed analysis was made for randomly chosen 26 strains isolated from 11 patients with Proteus mirabilis bacteremia. Using PFGE, we found that 10 (90.9%) isolates, collected from different clinical specimens of the same patient, were genetically identical.

Słowa kluczowe

EN

bacteremia; primary bacteremia; secondary bacteremia; Proteus; epidemiology; strain; antimicrobial susceptibility; biofilm formation; urinary tract; blood stream infection; human infection

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2018
• Tom: 67
• Numer: 4
• Opis fizyczny: p.471-478,fig.,ref.

Twórcy

autor

Kwiecinska-Pirog J.

• Department of Microbiology, Nicolaus Copernicus University in Torun, L.Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland

autor

Skowron K.

• Department of Microbiology, Nicolaus Copernicus University in Torun, L.Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland

autor

Gospodarek-Komkowska E.

• Department of Microbiology, Nicolaus Copernicus University in Torun, L.Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland

Bibliografia

• Ahn JY, Ann HW, Jeon Y, Ahn MY, Oh DH, Kim YC, Kim EJ, Song JE, Jung IY, Kim MH, et al. 2017. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea. BMC Infect Dis. 17:327.
• Armbruster CE, Mobley HLY. 2012. Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol. 10(11):743–754.
• CLSI. 2009. Performance Standards for Antimicrobial Disk Susceptibility Tests. 11th ed. CLSI standard M02. Wayne (USA): Clinical and Laboratory Standards Institute.
• Di Domenico EG, Farulla I, Prignano G, Gallo MT, Vespaziani M, Cavallo I, Sperduti I, Pontone M, Bordignon V, Cilli L, et al. 2017. Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype. Internat J Mol Sci, 18(5):1077.
• Di Pilato V, Chiarelli A, Boinett CJ, Riccobono E, Harris SR, D’Andrea M, Thomson NR,Rossolini GM, Giani T. 2016. Complete genome sequence of the first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream infection. Genome Announc. 4(3):e00607–16.
• Drzewiecka D. 2016. Significance and roles of Proteus spp. bacteria in natural environments. Microb Ecol. 72(4):741–758.
• Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. 2005. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 49:2598–2605.
• EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0 [Internet]. London (UK): The European Committee on Antimicrobial Susceptibility Testing; [cited 2018 June 27]. Available from http://www.eucast.org/clinical_breakpoints/
• Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J. 2003. Bacteremia due to tribe Proteeae: a review of 132 cases during a decade (1991–2000). Scand J Infect Dis. 35(2):98–103.
• Kwiecińska-Piróg J, Bogiel T, Gospodarek E. 2013a. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods. J Antibiot. 66(10):593–597.
• Kwiecińska-Piróg J, Skowron K, Zniszczoł K, Gospodarek E. 2013b. The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms. Biomed Res Int. 2013:1–8.
• Laupland KB, Church DL. 2014. Populations-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 27:647–664.
• Laupland KB, Parkins MD, Ross T, Pitout JDD. 2007. Population-based laboratory surveillance for tribe Proteeae isolates in a large Canadian health region. Clin Microbiol Infect. 13(7):683–688.
• Lebeaux D, Ghigo JM, Beloin C. 2014. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 78(3):510–543.
• O’Hara CM, Brenner FW, Miller JM. 2000. Classification, identification and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 13(4):534–546.
• Różalski A, Kwil I, Torzewska A, Baranowska M, Stączek P. 2007. Proteus bacilli: features and virulence factors. Post Hig Med Dosw. 61:204–219.
• Sabbuba NA, Mahenthiralingam E, Stickler DJ. 2003. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol. 41(11):4961–4965.
• Sohn KM, Kang ChI, Joo EJ, Ha YE, Chung DR, Peck KR, Lee NY, Song JH. 2011. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Proteus mirabilis bacteriemia. Korean J Intern Med. 26:89–93.
• Tumbarello M, Trecarichi EM, Fiori B, Losito AR, D’Inzeo T, Campana L, Ruggeri A, Di Meco E, Liberto E, Fadda G, et al. 2012. Multidrug-Resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 56(6):3224–3231.
• Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, Huang IW, Tan MC, Lauderdale TL. 2014. TSAR Hospitals. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC Infec Dis. 14(1):486.
• Watanakunakorn C, Perni SC. 1994. Proteus mirabilis bacteremia: a review of 176 cases during 1980–1992. Scand J Infect Dis. 26:361–367.

Identyfikatory

DOI

10.21307/pjm-2018-055